Peregrine Pharmaceuticals Inc., of Tustin, Calif., said it signed a new research collaboration with the National Comprehensive Cancer Network (NCCN) to expand the company's ongoing clinical research and development of bavituximab, which is designed to target phosphatidylserine, for the treatment of a range of tumors.